Network-Level Mechanisms for Preclinical Alzheimer's Disease Development
Status:
Active, not recruiting
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this project is to test the hypothesis that AGB101 low dose levetiracetam
extended release formulation can reduce abnormal hyperfunctional activity in the hippocampus
in normal, healthy adults who are APOE 4 carriers. The investigators will compare the results
to normal, healthy adults who are APOE 4 non-carriers.